CALA News and Press, Calithera Biosciences Inc. From 03/04/19

Here, I continue my coverage of the micro-cap oncology player AVEO Oncology ( AVEO ). In my previous piece , I discussed the issues AVEO encountered with the FDA regarding the results of the TIVO-1 trial, and how the FDA’s concerns may not be ameliorated by the available results of the...

SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today ann...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Calithera Biosciences ( CALA ) is a good speculative biotech to take a look at. It is using its clinical product CB-839 in combination with already approved therapies to tackle renal cell carcinoma. This approach could be worthwhile, especially since this biotech has two shots on goal to tac...

Updated data from a Phase 1 clinical trial evaluating Calithera Biosciences' ( CALA +4.1% ) glutaminase inhibitor telaglenastat, combined with Exelixis' ( EXEL -2.8% ) Cabometyx (cabozantinib), in previously treated patients with advanced renal cell carcinoma (RCC) showed a positive e...

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment...

Calithera Biosciences (NASDAQ: CALA ) has completed enrollment in its Phase 2 ENTRATA study evaluating the combination of telaglenastat (CB-839) and Novartis' Afinitor (everolimus) in patients with advanced renal cell carcinoma (RCC). More news on: Calithera Biosciences Read more .....

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment...